Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients

被引:33
作者
Fruendt, Thorben [1 ]
Krause, Linda [2 ]
Hussey, Elaine [1 ]
Steinbach, Bettina [3 ]
Koehler, Daniel [4 ]
von Felden, Johann [1 ]
Schulze, Kornelius [1 ]
Lohse, Ansgar W. [1 ]
Wege, Henning [1 ,5 ]
Schwarzenbach, Heidi [3 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, D-20246 Hamburg, Germany
[2] Inst Med Biometry & Epidemiol, D-20246 Hamburg, Germany
[3] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, D-20246 Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Dept Diagnost & Intervent Radiol & Nucl Med, D-20246 Hamburg, Germany
[5] Canc Ctr Esslingen, D-73730 Esslingen, Germany
关键词
microRNAs; exosomes; hepatocellular carcinoma; liver cirrhosis; survival prediction; BREAST-CANCER PATIENTS; CELL-FREE MICRORNAS; NEOADJUVANT THERAPY; NATURAL-HISTORY; SERUM-LEVELS; SORAFENIB; METASTASIS; MIR-373; COHORT;
D O I
10.3390/cancers13102484
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Exosomes, carrying small non-coding RNA (miRNA), are known to play a pivotal role in the process of tumor progression. In this prospective study, we identified miR-16, miR-146a, miR-192, and miR- 221 to be significantly deregulated in the plasma of patients with hepatocellular carcinoma (HCC) compared to patients with liver cirrhosis and healthy individuals. MiR-146a revealed diagnostic potential to differentiate HCC patients from liver cirrhosis patients with a sensitivity of 81% and a specificity of 58% in logistic regression model. Furthermore, miR- 192 independently correlated with overall survival in patients with HCC. We aimed to identify a specific microRNA (miRNA) pattern to determine diagnostic and prognostic value in plasma exosomes of hepatocellular carcinoma (HCC) patients. A two-stage study was carried out: exosomal miRNAs were quantified in plasma of HCC patients and healthy individuals by PCR-based microarray cards containing 45 different miRNAs (training cohort). Then, four deregulated miRNAs (miR-16, miR-146a, miR-192, and miR-221) were quantified in the validation analysis using exosomes derived from 85 HCC patients, 50 liver cirrhosis patients, and 20 healthy individuals. Exosomal miR-146a (p = 0.0001), miR-192 (p = 0.002) and miR-221 (p = 0.032) were upregulated only in HCC patients. Repeated 10-fold cross validation showed that miR-146a differentiated HCC from liver cirrhosis patients with AUC of 0.80 +/- 0.14 (sensitivity: 81 +/- 13%, specificity: 58 +/- 22%) in a logistic regression model. High miR-192 presence is associated with poor overall survival (OS) in all HCC patients (p = 0.027) and was predictor of OS in HCC patients in an uni- and multivariate Cox regression model. Moreover, decreased miR-16 levels correlated with OS in liver cirrhosis patients (p = 0.034). Our results emphasized that exosomes secreted into the plasma carry differentially expressed miRNAs of which in particular, miR-192, miR-146, and miR-16 are promising diagnostic and prognostic markers for both HCC and liver cirrhosis patients.
引用
收藏
页数:17
相关论文
共 48 条
  • [1] Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites
    Angeli, Paolo
    Gines, Pere
    Wong, Florence
    Bernardi, Mauro
    Boyer, Thomas D.
    Gerbes, Alexander
    Moreau, Richard
    Jalan, Rajiv
    Sarin, Shiv K.
    Piano, Salvatore
    Moore, Kevin
    Lee, Samuel S.
    Durand, Francois
    Salerno, Francesco
    Caraceni, Paolo
    Kim, W. Ray
    Arroyo, Vicente
    Garcia-Tsao, Guadalupe
    [J]. JOURNAL OF HEPATOLOGY, 2015, 62 (04) : 968 - 974
  • [2] Exosomes in cancer development, metastasis, and drug resistance: a comprehensive review
    Azmi, Asfar S.
    Bao, Bin
    Sarkar, Fazlul H.
    [J]. CANCER AND METASTASIS REVIEWS, 2013, 32 (3-4) : 623 - 642
  • [3] MicroRNAs: Target Recognition and Regulatory Functions
    Bartel, David P.
    [J]. CELL, 2009, 136 (02) : 215 - 233
  • [4] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
    Bruix, Jordi
    Qin, Shukui
    Merle, Philippe
    Granito, Alessandro
    Huang, Yi-Hsiang
    Bodoky, Gyrogy
    Pracht, Marc
    Yokosuka, Osamu
    Rosmorduc, Olivier
    Breder, Valeriy
    Gerolami, Rene
    Masi, Gianluca
    Ross, Paul J.
    Song, Tianqiang
    Bronowicki, Jean-Pierre
    Ollivier-Hourmand, Isabelle
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Llovet, Josep M.
    Finn, Richard S.
    LeBerre, Marie-Aude
    Baumhauer, Annette
    Meinhardt, Gerold
    Han, Guohong
    [J]. LANCET, 2017, 389 (10064) : 56 - 66
  • [5] Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
    Eichelser, Corinna
    Stueckrath, Isabel
    Mueller, Volkmar
    Milde-Langosch, Karin
    Wikman, Harriet
    Pantel, Klaus
    Schwarzenbach, Heidi
    [J]. ONCOTARGET, 2014, 5 (20) : 9650 - 9663
  • [6] Deregulated Serum Concentrations of Circulating Cell-Free MicroRNAs miR-17, miR-34a, miR-155, and miR-373 in Human Breast Cancer Development and Progression
    Eichelser, Corinna
    Flesch-Janys, Dieter
    Chang-Claude, Jenny
    Pantel, Klaus
    Schwarzenbach, Heidi
    [J]. CLINICAL CHEMISTRY, 2013, 59 (10) : 1489 - 1496
  • [7] EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
    Angeli P.
    Bernardi M.
    Villanueva C.
    Francoz C.
    Mookerjee R.P.
    Trebicka J.
    Krag A.
    Laleman W.
    Gines P.
    [J]. JOURNAL OF HEPATOLOGY, 2018, 69 (02) : 406 - 460
  • [8] Expression of Serum miR-16, let-7f, and miR-21 in Patients with Hepatocellular Carcinoma and their Clinical Significances
    Ge, Wei
    Yu, De-Cai
    Li, Qing-Guo
    Chen, Xi
    Zhang, Chen-Yu
    Ding, Yi-Tao
    [J]. CLINICAL LABORATORY, 2014, 60 (03) : 427 - 434
  • [9] RETRACTED: In vivo and in vitro effects of microRNA-221 on hepatocellular carcinoma development and progression through the JAK-STAT3 signaling pathway by targeting SOCS3 (Retracted article. See vol. 237, pg. 2000, 2022)
    Huang, Shan
    Zhou, Da
    Li, Yu-Xuan
    Ming, Zhi-Yong
    Li, Ke-Zhi
    Wu, Guo-Bin
    Chen, Chuang
    Zhao, Yin-Nong
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (04) : 3500 - 3514
  • [10] Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors
    Kanda, Miho
    Tateishi, Ryosuke
    Yoshida, Haruhiko
    Sato, Takahisa
    Masuzaki, Ryota
    Ohki, Takamasa
    Imamura, Jun
    Goto, Tadashi
    Yoshida, Hideo
    Hamamura, Keisuke
    Obi, Shuntaro
    Kanai, Fumihiko
    Shiina, Shuichiro
    Omata, Masao
    [J]. LIVER INTERNATIONAL, 2008, 28 (09) : 1256 - 1263